SPRO at a glance
Spero Therapeutics Inc (SPRO, SEC CIK 1701108) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 28, 2026 and Form 4 insider filings as recently as August 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Spero Therapeutics Inc (SPRO) reported revenue of $12.6 million (up 3292.5% from FY2024) and net income of $8.6 million. Diluted EPS was $0.15.
- As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Spero Therapeutics Inc (SPRO) shares worth $19.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $12.6M
- +3292.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $19.3M · +4 vs prior quarter
- Latest 10-Q
- Aug 12, 2026
- Quarterly report
SignalX for SPRO
Don't miss the next SPRO filing
- Alerts as it files. A push when SPRO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SPRO, by share count.
- Ask anything. An AI agent that reads every SPRO filing and answers with sources.
SPRO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Zack Debra | A | Aug 3, 2026 | 162,311 | - |
| Zack Debra | A | Aug 3, 2026 | 324,675 | - |
| THOMAS FRANK E | A | Jun 23, 2026 | 10,000 | - |
| Tregoning Kathleen | A | Jun 23, 2026 | 10,000 | - |
| Pottage John C Jr | A | Jun 23, 2026 | 10,000 | - |
| Pottage John C Jr | A | Jun 23, 2026 | 20,000 | - |
| Jackson Scott Thomas | A | Jun 23, 2026 | 10,000 | - |
| VINK PATRICK V.J.J. | A | Jun 23, 2026 | 10,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $933K | $371K | $12.6M |
| Operating Income | $21.5M | -$73.4M | $6.3M |
| Net Income | $22.8M | -$68.6M | $8.6M |
| Op. Margin | 2302.4% | -19773.9% | 50.2% |
| Net Margin | 2444.4% | -18481.4% | 68.1% |
| Balance Sheet | |||
| Total Assets | $182.4M | $110.5M | $68.9M |
| Equity | $106.9M | $46.1M | $59.0M |
| ROE | 21.3% | -148.7% | 14.5% |
| Per Share | |||
| EPS | - | $-1.27 | $0.15 |
| Cash Flow | |||
| Operating CF | -$33.0M | -$23.4M | -$12.6M |
Source: XBRL data in Spero Therapeutics Inc (SPRO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SPRO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 20 | $19.3M |
| Q1 2026 | 16 | $19.6M |
| Q4 2025 | 18 | $19.4M |
| Q3 2025 | 17 | $14.4M |
| Q2 2025 | 15 | $20.3M |
| Q1 2025 | 14 | $4.6M |
| Q4 2024 | 12 | $6.8M |
| Q3 2024 | 9 | $3.0M |
- Dimensional Fund Advisors+245.1K (+823%)
- Vanguard Capital Management LLC+236.3K (+13%)
- BlackRock+161.2K (+37%)
- Invesco Ltd+18.9K (+42%)
- Two Sigma Investments−502.8K (-57%)
- Renaissance Technologies LLC−241.3K (-20%)
- Northern Trust−12.7K (-11%)
- Citigroup−9.5K (-50%)
- Morgan Stanley−3.6K (-80%)
- Raymond James Financial+521.7K
- Goldman Sachs Group+257.0K
- Millennium Management+19.3K
- Prudential Financial+10.4K
- FMR LLC (Fidelity)+300
- Citadel Advisors LLC−376.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 121 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SPRO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SPRO SEC filings: frequently asked questions
Which institutions hold SPRO stock?
As of June 30, 2026, the largest Spero Therapeutics Inc (SPRO) holders among the 13F filers tracked by SignalX were Pfizer Inc ($5.3 million), Vanguard Capital Management LLC ($4.5 million), Renaissance Technologies LLC ($2.1 million), Alphabet Inc ($2.0 million), BlackRock ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SPRO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Spero Therapeutics Inc (SPRO) reported revenue of $12.6 million (up 3292.5% from FY2024) and net income of $8.6 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.
What are the latest SPRO SEC filings?
Spero Therapeutics Inc (SPRO) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 28, 2026 and a Form 4 insider filing on August 6, 2026.
What is SPRO's SEC CIK number?
Spero Therapeutics Inc (SPRO)'s SEC Central Index Key (CIK) is 1701108. EDGAR lists every SPRO filing under that number.
Ask anything about SPRO
The research agent reads SPRO's filings, financials, insider trades and 13F holders, then answers with sources.